Sort   by:  
 Page size 
ProteomicsLC-MS characterization of anti-PD-L1 and CXCR4 bispecific nanobodies
Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both targets are overexpressed i...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037102 | Pride
Nanobody Lc-ms Bispecific Protein Complete mw 
ProteomicsSpyMask Enables Combinatorial Assembly of Bispecific Binders
Bispecific antibodies are a successful and expanding therapeutic class, bridging two cell-types or engaging two different molecules on the same cell. Standard approaches to generate bispecifics are complicated by the need for disulfide reduction/oxidation or specialized formats. Here we present SpyM...
ORGANISM(S): Homo sapiens (Human) Escherichia coli 
2024-03-18 | PXD049393 | Pride
Chemical biology Immunotherapy Uncaging Tyrosine kinase Bifunctional 
ModelsSchropp2019 - Target-Mediated Drug Disposition Model for Bispecific Antibodies
This model presents a general target-mediated drug disposition (TMDD) model for bispecific antibodies (BsAbs), which bind to two different targets on different cell membranes. The model includes four different binding events for BsAbs, turnover of the targets, and internalization of the complexes. I...
2024-09-02 | BIOMD0000000788 | BioModels
ProteomicsNoncanonical amino acid-aided synthesis of anti-PD-L1 bispecific nanobody for colon cancer immunotherapy
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality, and the incidence of early-onset colon cancer has been increasing globally in recent years. The development of immunotherapies for colon cancer is critical for providing new treatment strategies to combat drug resistanc...
ORGANISM(S): Escherichia coli 
2026-01-12 | PXD069482 | Pride
Bispecific antibody Maldi-tof Noncanonical amino acid 
GenomicsTumor-Targeted Bispecific Antibodies Effectively Inhibit Oncogenic Pathways While Minimizing Toxicity
Bispecific Antibodies Inhibit Oncogenic Pathways
PRJEB102638 | ENA
GenomicsTandem bispecific IL-7 receptor agonist antibody
Tandem bispecific IL-7 receptor agonist antibody
PRJNA1327777 | ENA
GenomicsA CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy
PRJNA669680 | ENA
ProteomicsAn Unbiased Strategy for Selecting Effective Combinations of Therapeutic Targets Supports the Development of a Novel Bispecific Antibody with Tumor-Suppressing Properties
Recent progress in dissecting molecular mechanisms essential for the survival and propagation of cancer cells triggered rapid development of targeted therapies. Although many of these therapies produce impressive initial responses in tumor suppression, the onset of resistance is practically unavoida...
ORGANISM(S): Homo sapiens (Human) 
2023-01-27 | PXD023034 | Pride
Bispecific anti-egfr/epha2 antibody  epha2 receptor  bioid  proximity proteomics 
GenomicsDNA hypomethylating agents potentiate the efficacy of CD3 bispecific T cell engagers [scATAC-seq]
DNA hypomethylating agents potentiate the efficacy of CD3 bispecific T cell engagers [scATAC-seq]
PRJNA1366492 | ENA
GenomicsDNA hypomethylating agents potentiate the efficacy of CD3 bispecific T cell engagers [BiSulfite-seq]
DNA hypomethylating agents potentiate the efficacy of CD3 bispecific T cell engagers [BiSulfite-seq]
PRJNA1365923 | ENA
Sort   by:  
 Page size